Navigation Links
Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting
Date:5/15/2008

xane, and

Capecitabine Therapy

Poster 38A

Advanced Breast Oncologist and Patient Roles in June 2, 2008

Cancer Assessing Current and Future 2:00-6:00 p.m.

Abstract No: 1064 Treatment for Metastatic Location: S Hall

Breast Cancer: Results of an A1

Observational Linguistic study

Poster 32B

DACOGEN(R) A Multicenter Phase II Trial of June 2, 2008

(decitabine) the Decitabine Alternative 2:00-6:00 p.m.

Abstract No: 7032 5-day Dosing Regimen: Analysis Location: E450A

of Efficacy in Various

Subgroups of Patients with Poster

Myelodysplastic Syndromes discussion

Poster 21 5:00-6:00 p.m.

Location: E354A

DACOGEN(R) Cytogenetic Responses to a June 2, 2008

(decitabine) 5-Day Dosing Schedule of 2:00-6:00 p.m.

Abstract No: 7030 Decitabine in Patients with Location: E450A

Myelodysplastic Syndromes

Poster 19 Poster

discussion

5:00-6:00 p.m.

Location: E354A

ALOXI(R) Palonosetron (PALO) versus Accepted for

(palonosetron granisetron (GRAN), both publication

HCl) combined with dexamethasone only.

(DEX) in preventing


'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. GeoVax Secures $10 Million Financing Commitment
2. On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
3. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
4. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
5. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
6. Release of Cytopia Abstract for CYT997 Oral Presentation at American Society of Clinical Oncology
7. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
8. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
9. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
10. GlaxoSmithKline Reports Further Progress of Oncology Portfolio
11. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2008)...This analysis showed that Multaq(R) (dronedarone) ...h atrial fibrillation or atrial flutter already ...erapy, BRIDGEWATER, N.J., Sept. 3 /PRNewswire-Fir...he data from the ATHENA study were presented today...ean Society of Cardiology,congress 2008, in Munich...
(Date:9/3/2008)...hird Clinical Trial Reconfirms Strong Evidence Pyc...ave Lasting Effect on Joints Following Cessation ...N, N.J., Sept. 3 /- According to the ...the most common type of arthritis,is on the rise....ytotherapy,Research, reveals Pycnogenol(R), bark e...
(Date:9/2/2008)... NEW YORK, Sept. 3 /- Fore...os Almirall, S.A. today announced results from,two... novel long-acting,inhaled anticholinergic for the...lmonary disease (COPD). In both the ACCLAIM/COPD I...and Safety In Moderate to,Severe COPD Patients) st...
(Date:9/2/2008)... September is Prostate Cancer Awarene...Newswire/ -- September is,Prostate Cancer Awarenes...alm Beach announce a revolutionary new way to trea...nt courses of radiation. Prostate cancer is,the mo... Morse CyberKnife CEO, James G. Schwade, M.D., sa...
Breaking Medicine Technology:Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 2Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 3Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 6Alexza Announces Positive Phase 1 Results With AZ 007 28Staccato 28R 29 Zaleplon 29 1919 1Alexza Announces Positive Phase 1 Results With AZ 007 28Staccato 28R 29 Zaleplon 29 1919 2Alexza Announces Positive Phase 1 Results With AZ 007 28Staccato 28R 29 Zaleplon 29 1919 3Alexza Announces Positive Phase 1 Results With AZ 007 28Staccato 28R 29 Zaleplon 29 1919 4Measurements Poor for Assessing Clinical Trials With Children 17915 1Measurements Poor for Assessing Clinical Trials With Children 17915 21 in 4 U S Toddlers Improperly Vaccinated 17913 11 in 4 U S Toddlers Improperly Vaccinated 17913 21 in 4 U S Toddlers Improperly Vaccinated 17913 3Mylan Announces Final FDA Approval for Trandolapril Tablets 17911 1
...)--Apr 10, 2007 - Bentley,Pharmaceuticals, Inc. (N...ay announced that its abstract entitled "Interim,R...er,Pharmacokinetic Study of Intranasal Insulin Sp...ulin R(R)), Injectable Fast-Acting,Insulin (Humalo...e,I Diabetes Mellitus," has been selected for oral...
...2007 /PRNewswire-FirstCall/ -- Kosan,Biosciences I...e,Company,s clinical and preclinical pipeline, inc... export inhibitor programs, at the,2007 Annual Mee...ch,(AACR), being held in Los Angeles, April 14-18,...are as follows. The,location for all poster presen...
Other Medicine Technology:Nasulin Interim Results to Be Presented at American Diabetes,Association Scientific Sessions 2Nasulin Interim Results to Be Presented at American Diabetes,Association Scientific Sessions 3Kosan Announces Data Presentations at Upcoming AACR Annual Meeting 2Kosan Announces Data Presentations at Upcoming AACR Annual Meeting 3
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...epressants increase the risk of a gastrointestinal...reuptake inhibitors (SSRIs) are a group of antidep...e preferred over older drugs because they are rela...at Ottawa Hospital in Canada have just shown, they...
... that they "enjoy" their habit and don't fear the ...king involves powerful physiological and psycholog...ithout help only a minority succeed. Even smoking ...e helpful to many, have been unable to keep the ma...
...twice as likely to have a better quality of life a...uggests. Researchers in a Swiss study looked at pa... chronic angina. Doctors either gave them medicat...ty - a treatment where a fine tube with a small in...
...Centre and the Pentagon could affect the mental he... the dust settles over New York and Washington, ps...e full psychological impact of the disaster. Keepi...al keeps anxiety and grief at bay. And the sheer s...
Other Medicine News:
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
Medicine Products: